A Phase 2b, Single-Arm, Open-Label, Multicenter Study of the Safety of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
Latest Information Update: 06 Jun 2026
At a glance
- Drugs RG 6797 (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Roche
Most Recent Events
- 26 May 2026 Planned initiation date changed from 15 May 2026 to 30 Jun 2026.
- 27 Apr 2026 Planned initiation date changed from 31 Mar 2026 to 15 May 2026.
- 27 Apr 2026 Status changed from not yet recruiting to recruiting.